NCT03542695View on ClinicalTrials.gov

64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Breast CarcinomaCalcification
Interventions
PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Copper Cu-64-DOTA-alendronate

Given IV

OTHER

Pharmacokinetic Study

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03542695 - 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy | Biotech Hunter | Biotech Hunter